Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727234 | 0.85 | FAAH (0.56) | CASP2TLR2MAPK1 | |
| SCHEMBL15914739 | 0.83 | EPHX1 (0.45) | EPHX1MTNR1AMTNR1BATMMAPK1 | |
| SCHEMBL2354778 | 0.83 | EPHX1 (0.40) | EPHX1ATMTLR2MAPK1 | |
| SCHEMBL10710177 | 0.80 | EPHX1 (0.43) | EPHX1ATMMAPK1 | |
| SCHEMBL5611916 | 0.78 | CASP2 (0.55) | EPHX1CASP2 | |
| SCHEMBL26118270 | 0.78 | EPHX2 (0.56) | — | |
| SCHEMBL10008936 | 0.77 | CYP2D6 (0.50) | EPHX1ATMMAPK1 | |
| SCHEMBL10314187 | 0.77 | EPHX1 (0.46) | EPHX1MTNR1AMTNR1BATMMAPK1 | |
| SCHEMBL11779858 | 0.75 | EPHX1 (0.45) | EPHX1ATMMAPK1 | |
| SCHEMBL24462465 | 0.74 | CASP2 (0.48) | CASP2HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296681-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8604244-B2 | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012003501-A2 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | PNMT, TPH1, TPH2 | EPHX1 1661/4885CASP2 4159/4885HDAC3 91/4885 |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | TPH1, TPH2, PNMT | EPHX1 1396/4885CASP2 4491/4885HDAC3 79/4885 |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, TPH1, TPH2 | EPHX1 1502/4885CASP2 4240/4885HDAC3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.